Antibe Therapeutics (CVE:ATE) Reaches New 52-Week High at $0.43

Antibe Therapeutics Inc (CVE:ATE) shares reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as C$0.43 and last traded at C$0.43, with a volume of 2369054 shares. The stock had previously closed at C$0.39.

The company has a market cap of $93.23 million and a P/E ratio of -7.00. The firm has a 50 day moving average price of C$0.33 and a 200-day moving average price of C$0.31. The company has a debt-to-equity ratio of 27.85, a quick ratio of 2.51 and a current ratio of 3.63.

About Antibe Therapeutics (CVE:ATE)

Antibe Therapeutics Inc, a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, and the United States. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase IIB gastrointestinal safety study.

Further Reading: What Are Cryptocurrencies?

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with's FREE daily email newsletter.